In ER-positive HER2-negative early breast cancer patients, one of the several available genetic prognostic platforms (Oncotype DX®, MammaPrint®, Prosigna®, or EndoPredict®) may be used to establish prognosis and to discuss with the patient whether adjuvant treatment may be limited to hormonal therapy. This evidence concerns the gene ESR1 and breast cancer.